Drug interactions should be evaluated in patients

Research output: Contribution to journalComment/debate

12 Citations (Scopus)

Abstract

Drug development involves learning and confirming in healthy volunteers and ultimately in patients. This approach should apply to drug-drug interactions because requirements to extrapolate pharmacokinetic and pharmacodynamic findings from healthy volunteers to patients are not uniformly met, and the designs of interaction studies often have little relevance to actual clinical use. Guidance to health-care professionals on a safe and effective dose for individual patients should include information from drug-drug interaction studies in the intended patients.

Original languageEnglish (US)
Pages (from-to)585-587
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number5
DOIs
StatePublished - Jan 1 2010

Fingerprint

Drug Interactions
Healthy Volunteers
Pharmaceutical Preparations
Pharmacokinetics
Learning
Delivery of Health Care

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Drug interactions should be evaluated in patients. / Fletcher, Courtney V.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 5, 01.01.2010, p. 585-587.

Research output: Contribution to journalComment/debate

@article{899c7203f6cd437dafdaddde880b9b2e,
title = "Drug interactions should be evaluated in patients",
abstract = "Drug development involves learning and confirming in healthy volunteers and ultimately in patients. This approach should apply to drug-drug interactions because requirements to extrapolate pharmacokinetic and pharmacodynamic findings from healthy volunteers to patients are not uniformly met, and the designs of interaction studies often have little relevance to actual clinical use. Guidance to health-care professionals on a safe and effective dose for individual patients should include information from drug-drug interaction studies in the intended patients.",
author = "Fletcher, {Courtney V}",
year = "2010",
month = "1",
day = "1",
doi = "10.1038/clpt.2010.213",
language = "English (US)",
volume = "88",
pages = "585--587",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Drug interactions should be evaluated in patients

AU - Fletcher, Courtney V

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Drug development involves learning and confirming in healthy volunteers and ultimately in patients. This approach should apply to drug-drug interactions because requirements to extrapolate pharmacokinetic and pharmacodynamic findings from healthy volunteers to patients are not uniformly met, and the designs of interaction studies often have little relevance to actual clinical use. Guidance to health-care professionals on a safe and effective dose for individual patients should include information from drug-drug interaction studies in the intended patients.

AB - Drug development involves learning and confirming in healthy volunteers and ultimately in patients. This approach should apply to drug-drug interactions because requirements to extrapolate pharmacokinetic and pharmacodynamic findings from healthy volunteers to patients are not uniformly met, and the designs of interaction studies often have little relevance to actual clinical use. Guidance to health-care professionals on a safe and effective dose for individual patients should include information from drug-drug interaction studies in the intended patients.

UR - http://www.scopus.com/inward/record.url?scp=77958512004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958512004&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.213

DO - 10.1038/clpt.2010.213

M3 - Comment/debate

VL - 88

SP - 585

EP - 587

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -